BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 19118004)

  • 1. Identification of an indispensable role for tyrosine kinase 2 in CTL-mediated tumor surveillance.
    Simma O; Zebedin E; Neugebauer N; Schellack C; Pilz A; Chang-Rodriguez S; Lingnau K; Weisz E; Putz EM; Pickl WF; Felzmann T; Müller M; Decker T; Sexl V; Stoiber D
    Cancer Res; 2009 Jan; 69(1):203-11. PubMed ID: 19118004
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Organ-specific and differential requirement of TYK2 and IFNAR1 for LPS-induced iNOS expression in vivo.
    Painz R; Walter I; Kolbe T; Rigler D; Vogl C; Steinborn R; Rülicke T; Helmreich M; Karaghiosoff M; Müller M
    Immunobiology; 2007; 212(9-10):863-75. PubMed ID: 18086385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Notch2 signaling is required for potent antitumor immunity in vivo.
    Sugimoto K; Maekawa Y; Kitamura A; Nishida J; Koyanagi A; Yagita H; Kojima H; Chiba S; Shimada M; Yasutomo K
    J Immunol; 2010 May; 184(9):4673-8. PubMed ID: 20351182
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Control of Leishmania major in the absence of Tyk2 kinase.
    Schleicher U; Mattner J; Blos M; Schindler H; Röllinghoff M; Karaghiosoff M; Müller M; Werner-Felmayer G; Bogdan C
    Eur J Immunol; 2004 Feb; 34(2):519-29. PubMed ID: 14768057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An important role of Tyk2 in APC function of dendritic cells for priming CD8+ T cells producing IFN-gamma.
    Aizu K; Li W; Yajima T; Arai T; Shimoda K; Nimura Y; Yoshikai Y
    Eur J Immunol; 2006 Nov; 36(11):3060-70. PubMed ID: 17048270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An indispensable role of type-1 IFNs for inducing CTL-mediated complete eradication of established tumor tissue by CpG-liposome co-encapsulated with model tumor antigen.
    Wakita D; Chamoto K; Zhang Y; Narita Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Int Immunol; 2006 Mar; 18(3):425-34. PubMed ID: 16415100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary T-cell and activated macrophage response associated with tumor protection using peptide/poly-N-acetyl glucosamine vaccination.
    Maitre N; Brown JM; Demcheva M; Kelley JR; Lockett MA; Vournakis J; Cole DJ
    Clin Cancer Res; 1999 May; 5(5):1173-82. PubMed ID: 10353754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis.
    Oyamada A; Ikebe H; Itsumi M; Saiwai H; Okada S; Shimoda K; Iwakura Y; Nakayama KI; Iwamoto Y; Yoshikai Y; Yamada H
    J Immunol; 2009 Dec; 183(11):7539-46. PubMed ID: 19917699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Th2-type CD4+ cells neither enhance nor suppress antitumor CTL activity in a mouse tumor model.
    Fernando GJ; Stewart TJ; Tindle RW; Frazer IH
    J Immunol; 1998 Sep; 161(5):2421-7. PubMed ID: 9725239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CTLA-4 ablation and interleukin-12 driven differentiation synergistically augment cardiac pathogenicity of cytotoxic T lymphocytes.
    Love VA; Grabie N; Duramad P; Stavrakis G; Sharpe A; Lichtman A
    Circ Res; 2007 Aug; 101(3):248-57. PubMed ID: 17569889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An essential role of antigen-presenting cell/T-helper type 1 cell-cell interactions in draining lymph node during complete eradication of class II-negative tumor tissue by T-helper type 1 cell therapy.
    Chamoto K; Wakita D; Narita Y; Zhang Y; Noguchi D; Ohnishi H; Iguchi T; Sakai T; Ikeda H; Nishimura T
    Cancer Res; 2006 Feb; 66(3):1809-17. PubMed ID: 16452242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 partially protects renal tubular epithelial cells from the attack of CD8+ cytotoxic T cells.
    Waeckerle-Men Y; Starke A; Wüthrich RP
    Nephrol Dial Transplant; 2007 Jun; 22(6):1527-36. PubMed ID: 17339272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hapten-induced contact hypersensitivity is enhanced in Tyk2-deficient mice.
    Hosogi M; Tonogaito H; Aioi A; Hamada K; Shimoda K; Muromoto R; Matsuda T; Miyachi Y
    J Dermatol Sci; 2004 Oct; 36(1):51-6. PubMed ID: 15488705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.
    Zhang J; Zhou Z; Wang C; Shen J; Zheng Y; Zhang L; Wang J; Xia D
    Cancer Immunol Immunother; 2011 Apr; 60(4):559-73. PubMed ID: 21240488
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an interferon-gamma-inducible carcinoembryonic antigen (CEA) CD8(+) T-cell epitope, which mediates tumor killing in CEA transgenic mice.
    Schmitz J; Reali E; Hodge JW; Patel A; Davis G; Schlom J; Greiner JW
    Cancer Res; 2002 Sep; 62(17):5058-64. PubMed ID: 12208761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide.
    Kikuchi T; Uehara S; Ariga H; Tokunaga T; Kariyone A; Tamura T; Takatsu K
    Immunology; 2006 Jan; 117(1):47-58. PubMed ID: 16423040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Archaeosomes induce enhanced cytotoxic T lymphocyte responses to entrapped soluble protein in the absence of interleukin 12 and protect against tumor challenge.
    Krishnan L; Sad S; Patel GB; Sprott GD
    Cancer Res; 2003 May; 63(10):2526-34. PubMed ID: 12750276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tyrosine kinase 2 is not limiting human antiviral type III interferon responses.
    Fuchs S; Kaiser-Labusch P; Bank J; Ammann S; Kolb-Kokocinski A; Edelbusch C; Omran H; Ehl S
    Eur J Immunol; 2016 Nov; 46(11):2639-2649. PubMed ID: 27615517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor apoptotic bodies inhibit CTL responses and antitumor immunity via membrane-bound transforming growth factor-beta1 inducing CD8+ T-cell anergy and CD4+ Tr1 cell responses.
    Xie Y; Bai O; Yuan J; Chibbar R; Slattery K; Wei Y; Deng Y; Xiang J
    Cancer Res; 2009 Oct; 69(19):7756-66. PubMed ID: 19789353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic limitations in tumor-specific CD8+ memory T cell engraftment.
    Bathe OF; Dalyot-Herman N; Malek TR
    BMC Cancer; 2003 Jul; 3():21. PubMed ID: 12882650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.